Abstract
Part II of this continuing medical education article will discuss the treatment options for stage IV melanoma, including novel therapies, such as ipilimumab and vemurafenib; established therapies, including high-dose interleukin-2, conventional chemotherapy, and biochemotherapy; and additional therapies currently under investigation in the form of clinical trials. The approach to patients with brain metastases will be discussed, as will recommendations for distress screening and defining aspects of palliative care.
Copyright © 2012 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use
-
Antineoplastic Agents / therapeutic use
-
Brain Neoplasms / secondary*
-
Brain Neoplasms / therapy*
-
Dacarbazine / therapeutic use
-
Humans
-
Immunologic Factors / therapeutic use
-
Indoles / therapeutic use
-
Interleukin-2 / therapeutic use
-
Ipilimumab
-
Melanoma / secondary*
-
Melanoma / therapy*
-
Neoplasm Staging
-
Palliative Care*
-
Protein-Tyrosine Kinases / antagonists & inhibitors
-
Proto-Oncogene Proteins c-kit / genetics
-
Radiosurgery
-
Skin Neoplasms / pathology*
-
Skin Neoplasms / therapy*
-
Sulfonamides / therapeutic use
-
Vemurafenib
-
raf Kinases / antagonists & inhibitors
Substances
-
Antibodies, Monoclonal
-
Antineoplastic Agents
-
Immunologic Factors
-
Indoles
-
Interleukin-2
-
Ipilimumab
-
Sulfonamides
-
Vemurafenib
-
Dacarbazine
-
Protein-Tyrosine Kinases
-
Proto-Oncogene Proteins c-kit
-
raf Kinases